
-
Reagents
- Flow Cytometry Reagents
-
Western Blotting and Molecular Reagents
- Immunoassay Reagents
-
Single-Cell Multiomics Reagents
- BD® OMICS-Guard Sample Preservation Buffer
- BD® AbSeq Assay
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Protein Panels
-
Functional Assays
-
Microscopy and Imaging Reagents
-
Cell Preparation and Separation Reagents
-
- BD® OMICS-Guard Sample Preservation Buffer
- BD® AbSeq Assay
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Protein Panels
- Poland (English)
-
Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Pharmingen™ PE Mouse Anti-Human VEGFR2 (CD309)
Clone BB13-1044 (RUO)

Flow cytometric analysis of Human VEGFR2 (CD309) expression on viable HUVEC cells. Human Umbilical Vein Endothelial Cells (HUVEC; Lonza, Cat. No. C2519A) were grown in EGM®-2 Endothelial Cell Growth Medium (Lonza, Cat No. CC-3162), which contains Vascular endothelial growth factor (VEGF), and were dissociated with Reagent Pack™ Subculture Reagents (Lonza, Cat No. CC-5034). The cells were preincubated with Human BD Fc Block™ (Cat. No. 564219) and stained with either PE Mouse IgG1, κ Isotype Control (Cat. No. 554680; dashed line histograms) or PE Mouse Anti-Human VEGFR2 (CD309) antibody (Cat. No. 571194/571200; solid line histograms). DAPI Solution (Cat. No. 564907) was added to cells right before analysis. The fluorescence histograms showing VEGFR2 (CD309) expression (or Ig Isotype control staining) were derived from gated events with the light-scatter characteristics of viable (DAPI-negative) cells. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.


Flow cytometric analysis of Human VEGFR2 (CD309) expression on viable HUVEC cells. Human Umbilical Vein Endothelial Cells (HUVEC; Lonza, Cat. No. C2519A) were grown in EGM®-2 Endothelial Cell Growth Medium (Lonza, Cat No. CC-3162), which contains Vascular endothelial growth factor (VEGF), and were dissociated with Reagent Pack™ Subculture Reagents (Lonza, Cat No. CC-5034). The cells were preincubated with Human BD Fc Block™ (Cat. No. 564219) and stained with either PE Mouse IgG1, κ Isotype Control (Cat. No. 554680; dashed line histograms) or PE Mouse Anti-Human VEGFR2 (CD309) antibody (Cat. No. 571194/571200; solid line histograms). DAPI Solution (Cat. No. 564907) was added to cells right before analysis. The fluorescence histograms showing VEGFR2 (CD309) expression (or Ig Isotype control staining) were derived from gated events with the light-scatter characteristics of viable (DAPI-negative) cells. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.

Flow cytometric analysis of Human VEGFR2 (CD309) expression on viable HUVEC cells. Human Umbilical Vein Endothelial Cells (HUVEC; Lonza, Cat. No. C2519A) were grown in EGM®-2 Endothelial Cell Growth Medium (Lonza, Cat No. CC-3162), which contains Vascular endothelial growth factor (VEGF), and were dissociated with Reagent Pack™ Subculture Reagents (Lonza, Cat No. CC-5034). The cells were preincubated with Human BD Fc Block™ (Cat. No. 564219) and stained with either PE Mouse IgG1, κ Isotype Control (Cat. No. 554680; dashed line histograms) or PE Mouse Anti-Human VEGFR2 (CD309) antibody (Cat. No. 571194/571200; solid line histograms). DAPI Solution (Cat. No. 564907) was added to cells right before analysis. The fluorescence histograms showing VEGFR2 (CD309) expression (or Ig Isotype control staining) were derived from gated events with the light-scatter characteristics of viable (DAPI-negative) cells. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ Software.


BD Pharmingen™ PE Mouse Anti-Human VEGFR2 (CD309)

Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cell and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
Companion Products





The BB13-1044 monoclonal antibody specifically recognizes Vascular endothelial growth factor receptor 2 (VEGFR-2) which is also known as CD309 and Fetal liver kinase 1 (FLK-1). This protein receptor tyrosine kinase is an ~230 kDa single pass type I transmembrane glycoprotein that is encoded by KDR (Kinase insert domain receptor). It is variably expressed by mesodermal and endothelial cells in embryonic tissues and by vascular endothelial cells, megakaryocytes, platelets, retinal progenitors, and smooth muscle cells in normal adult or tumor tissues. The N-terminal extracellular region of CD309 (VEGFR-2) consists of seven IgC2-like domains which are followed by a single transmembrane region and a C-terminal intracellular tyrosine kinase. The first three extracellular domains mediate ligand binding whereas the remaining four are involved in receptor dimerization. CD309 (VEGFR-2) functions as a receptor for several Vascular endothelial growth factor (VEGF) isoforms. Following receptor dimerization upon ligand binding, CD309 (VEGFR-2) autophosphorylates and stimulates the proliferation and migration of endothelial and other cell types.

Development References (3)
-
Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Res. 1992; 13(1):18-32. (Biology). View Reference
-
Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008; 453(7194):524-528. (Biology). View Reference
-
Ziegler BL, Valtieri M, Porada GA, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999; 285:1553-1558. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.